Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Full description

Bibliographic Details
Published in:Scientific Reports
Main Author: Lee H.-C.; Hamzah H.; Leong M.P.-Y.; Md Yusof H.; Habib O.; Zainal Abidin S.; Seth E.A.; Lim S.-M.; Vidyadaran S.; Mohd Moklas M.A.; Abdullah M.A.; Nordin N.; Hassan Z.; Cheah P.-S.; Ling K.-H.
Format: Article
Language:English
Published: Nature Research 2021
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101446415&doi=10.1038%2fs41598-021-83222-z&partnerID=40&md5=bd59ec493f7c72b6d7626540688eb66f

Similar Items